Cormorant Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Cormorant Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,655,000	Closed	-$178M	–	83
2023 Q1	$178M	Sell	1,655,000 -435,000	-21%	-$50.1M	11.7%	1
2022 Q4	$230M	Buy	2,090,000 +110,842	+6%	+$7.19M	15.38%	1
2022 Q3	$117M	Sell	1,979,158 -50,000	-2%	-$2.29M	8.16%	1
2022 Q2	$57.3M	Buy	2,029,158 +205,714	+11%	+$5.96M	4.33%	4
2022 Q1	$68.9M	Sell	1,823,444 -24,580	-1%	-$972K	5.29%	4
2021 Q4	$73.1M	Hold	1,848,024	–	–	4.35%	4
2021 Q3	$43.8M	Hold	1,848,024	–	–	1.78%	16
2021 Q2	$44.5M	Sell	1,848,024 -250,000	-12%	-$5.58M	1.51%	21
2021 Q1	$36.6M	Buy	+2,098,024	New	+$43.3M	0.82%	33

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Cormorant Asset Management's RXDX Position: Q2 2023 in Review

Cormorant Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,655,000 shares — an estimated $178M sold.

Cormorant Asset Management first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $230M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Cormorant Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Cormorant Asset Management sold 1,655,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $178M.
Cormorant Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Cormorant Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $230M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.